IFNG and glioblastoma: To assess the development of endogenous anti-tumor activity, fresh PBMC were tested for cytotoxic T lymphocyte (CTL) activity by measuring the IFN-γ ELISpots upon stimulation with GBM cell line U87 and NK cell-specific target K562 preimmunotherapy (PreIT) and post-immunotherapy time points (PostIT).